SCHEMBL14224670

SCHEMBL14224670

Cn1cc(N)cc1-c1nc2cc(O)ccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 2/20 0.40
KDM4E B2RXH2 3/20 0.40
NPC1 O15118 3/20 0.40
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PLAU P00749 1/20 0.38
ALDH1A1 P00352 4/20 0.35
HPGD P15428 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
HSD17B10 Q99714 4/20 0.35
MAPT P10636 2/20 0.35
USP2 O75604 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CHEK1 O14757 1/20 0.35
PRKD3 O94806 1/20 0.35
PAK4 O96013 1/20 0.35
PDGFRA P16234 1/20 0.35
LTK P29376 1/20 0.35
MAP2K2 P36507 1/20 0.35
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16329516 0.82 RAB9A (0.41) KDM4ENPC1RECQLNPSR1SMN1; SMN2
SCHEMBL14224532 0.82 NPC1 (0.60) KDM4ENPC1RECQLNPSR1ALDH1A1
SCHEMBL17919529 0.81 NPC1 (0.37) KDM4ENPC1RECQLNPSR1ALDH1A1
SCHEMBL12392511 0.79 KDM4E (0.35) KDM4ENPC1RECQLNPSR1SMN1; SMN2
SCHEMBL15224068 0.79 MAPK1 (0.40) KDM4ENPC1RECQLNPSR1PLAU
SCHEMBL14224669 0.79 MEN1 (0.49) NPC1ALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL14224791 0.78 KDM4E (0.40) KDM4ENPC1RECQLNPSR1ALDH1A1
SCHEMBL5333120 0.78 FGFR1 (0.50) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL14426911 0.77 RAB9A (0.44) KDM4ESMN1; SMN2MAPTUSP2TDP1
SCHEMBL24630455 0.77 RAB9A (0.56) KDM4ENPC1RECQLALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS GENESOFT PHARMACEUTICALS, INC. (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090816-A1 ANTI-INFECTIVE BIARYL COMPOUNDS QTRT1, Q6ZSR9, QTRT2 AMY1A 4335/4885KDM4E 3096/4885NPC1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.